Blossom Gold Inc. has received approval to trade its common shares on the OTCQX Best Market in the United States under the ticker BGAUF, effective October 20, 2026. This move complements its existing listing on the Toronto Stock Exchange and aims to broaden its shareholder base by improving trading access for U.S. investors. The OTCQX listing enhances visibility and provides U.S. investors with real-time quotes and easier trading through U.S. brokerage platforms. Blossom Gold focuses on developing the Rosebud Project, a precious metals exploration site with significant gold and silver resources in Nevada.
Blossom Gold's OTCQX approval is noted here with Pluang's Basic Materials sector data as of Oct 20, 2026 03:42 WIB. Of 83 priced US stocks, 31 rose and 51 fell. Notable movers include MP at USD 39.09 with a -2.69% change and 75% buy order activity, Aspen Aerogels at USD 5.32 up 2.50%, and Gold Fields at USD 36.69 down 2.42% with 83% buy orders.
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
